Skip to main content

Table 2 Event Incidence and Hazard Ratios with 95% Confidence Intervals for IPTW Analysis of the Rivaroxaban and Warfarin Cohorts Using an Intent-To-Treat Approach

From: Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis

 

Rivaroxaban

N = 2097

n (%)

Warfarin

N = 2842

n (%)

HR (95%CI)

3-Month

 Composite of recurrent venous thromboembolism or major bleeding

96 (4.58)

130 (4.57)

1.08 (0.82–1.42)

 Recurrent venous thromboembolism

74 (3.53)

96 (3.38)

1.07 (0.78–1.46)

 Major bleeding

27 (1.29)

40 (1.41)

1.19 (0.72–1.97)

 Intracranial hemorrhage

2 (0.10)

5 (0.18)

0.66 (0.12–3.59)

 Gastrointestinal bleeding

17 (0.81)

24 (0.84)

1.16 (0.61–2.21)

 Genitourinary bleeding

4 (0.19)

6 (0.21)

1.08 (0.30–3.93)

6-Month

 Composite of recurrent venous thromboembolism or major bleeding

105 (5.01)

166 (5.84)

0.96 (0.75–1.24)

 Recurrent venous thromboembolism

81 (3.86)

115 (4.05)

1.01 (0.76–1.36)

 Major bleeding

30 (1.43)

59 (2.08)

0.93 (0.59–1.47)

 Intracranial hemorrhage

2 (0.10)

7 (0.25)

0.50 (0.10–2.50)

 Gastrointestinal bleeding

18 (0.86)

37 (1.30)

0.84 (0.47–1.51)

 Genitourinary bleeding

4 (0.19)

9 (0.32)

0.80 (0.24–2.63)

12-Month

 Composite of recurrent venous thromboembolism or major bleeding

122 (5.82)

208 (7.32)

0.93 (0.74–1.16)

 Recurrent venous thromboembolism

89 (4.24)

140 (4.93)

0.95 (0.72–1.2)

 Major bleeding

39 (1.86)

80 (2.81)

0.92 (0.62–1.36)

 Intracranial hemorrhage

5 (0.24)

13 (0.46)

0.76 (0.27–2.19)

 Gastrointestinal bleeding

21 (1.00)

47 (1.65)

0.80 (0.47–1.37)

 Genitourinary bleeding

5 (0.24)

10 (0.35)

0.88 (0.29–2.63)

  1. CI Confidence interval, HR Hazard ratio, N Number